CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to OMER

Biological: narsoplimab

Phase 2
Omeros Corporation (OMER)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Thrombotic Microangiopathies

View Full Landscape
Drug Information

Target Indication

Thrombotic Microangiopathies

Clinical Trial

NCT05855083

Last updated: 12/19/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Yartemlea

Treatment of patients with haemopoietic stem cell transplant-associated thrombotic microangiopathy

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.